DGIdb - VORINOSTAT Drug Record

VORINOSTAT chembl:CHEMBL98 ApprovedAntineoplasticImmunotherapy

Alternate Names:

MK0683
VORINOSTAT
MK-0683
ZOLINZA
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
SHH
SUBEROYLANILIDE HYDROXAMIC ACID
SAHA
SUBERANILOHYDROXAMIC ACID
pubchem.compound:5311
chembl:CHEMBL98
chemidplus:149647-78-9
drugbank:02546
rxcui:194337

Drug Info:

Year of Approval	2006
Drug Class	antineoplastic agents
FDA Approval	Cutaneous T-cell lymphoma
Drug Class	Small molecule inhibitor
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent

(11 More Sources)

Publications:

Guerrant W et al., 2013, Dual-acting histone deacetylase-topoisomerase I inhibitors., Bioorg Med Chem Lett
Hutt DM et al., 2010, Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis., Nat Chem Biol
Yang W et al., 2015, Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors., Bioorg Med Chem
Daniel KB et al., 2015, Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release., J Med Chem
Neelarapu R et al., 2011, Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes., J Med Chem
Souto JA et al., 2010, Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues., J Med Chem
Dallavalle S et al., 2009, Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors., Eur J Med Chem
Guerrant W et al., 2012, Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors., J Med Chem
Grolla AA et al., 2009, Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases., J Med Chem
Pérez-Balado C et al., 2007, Bispyridinium dienes: histone deacetylase inhibitors with selective activities., J Med Chem
Li X et al., 2014, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity., J Med Chem
Olson DE et al., 2013, Discovery of the first histone deacetylase 6/8 dual inhibitors., J Med Chem
Xu et al., 2007, Histone deacetylase inhibitors: molecular mechanisms of action., Oncogene
Day JA et al., 2013, Investigating the selectivity of metalloenzyme inhibitors., J Med Chem
Dalgard et al., 2008, Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma., Clin. Cancer Res.
Rushlow et al., 2013, Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies., Lancet Oncol.
Landreville et al., 2012, Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma., Clin. Cancer Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Mai A et al., 2008, Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities., Bioorg Med Chem Lett
He et al., 2013, Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma., Cancer Discov
Lee HY et al., 2014, Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells., J Med Chem
Kemp MM et al., 2011, A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold., Bioorg Med Chem Lett
Moffat D et al., 2010, Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor., J Med Chem
Sodji QH et al., 2013, Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors., J Med Chem
Yao Y et al., 2015, Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities., J Med Chem
Johnson et al., 2015, HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma., Oncotarget
Kerl et al., 2013, The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells., BMC Cancer
Fu et al., 2015, Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation., Ann. Oncol.
Alexandrova et al., 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment., Nature
New et al., 2016, TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism., Cancer Res.
Xu et al., 2005, The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines., Int. J. Mol. Med.
Vinik et al., 2016, Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial., Target Oncol
Geeleher P et al., 2015, Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics., J Natl Cancer Inst
Vlietstra et al., 1998, Frequent inactivation of PTEN in prostate cancer cell lines and xenografts., Cancer Res.
Qian et al., 2012, Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling., Clin. Cancer Res.
Garcia et al., 2016, Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species., Clin. Cancer Res.
Kulp et al., 2006, Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer., Clin. Cancer Res.

VORINOSTAT CHD4

Interaction Score: 2.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26296641

Sources:
PharmGKB
VORINOSTAT HDAC6

Interaction Score: 0.69

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Merck

Novel drug target Established target

Mechanism of Interaction Histone deacetylase 6 inhibitor

PMIDs:
23622981 19966789 24766560 26211462 21696956 21080647 21548582 20491440 24304348 26331334 19084294 23672185 22260166 19344175 17694093

Sources:
TALC DTC TdgClinicalTrial ChemblInteractions TEND
VORINOSTAT HDAC2

Interaction Score: 0.62

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Histone deacetylase 2 inhibitor

Direct Interaction yes

PMIDs:
23622981 19966789 26211462 21548582 20491440 23672185 19084294 22260166 19344175 24074025 17447750 24694055 17694093

Sources:
TALC DTC TdgClinicalTrial ChemblInteractions TEND
VORINOSTAT HDAC3

Interaction Score: 0.6

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Histone deacetylase 3 inhibitor

Notes

PMIDs:
17447750 23622981 19966789 26211462 24694055 23672185 21548582 20491440 19084294 22260166 19344175 17694093

Sources:
TALC DTC TdgClinicalTrial ChemblInteractions TEND
VORINOSTAT HDAC1

Interaction Score: 0.57

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Histone deacetylase 1 inhibitor

Direct Interaction yes

Trial Name Merck

PMIDs:
17694093 11752352 23622981 19966789 26211462 21548582 20491440 24694055 19084294 23672185 22260166 19344175 18381238

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND TTD
VORINOSTAT MYD88

Interaction Score: 0.54

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type diffuse large B-cell lymphoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
27733371

Sources:
JAX-CKB
VORINOSTAT HDAC9

Interaction Score: 0.5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources:
TALC DTC MyCancerGenome ClearityFoundationClinicalTrial
VORINOSTAT HDAC11

Interaction Score: 0.49

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources:
TALC DTC ClearityFoundationClinicalTrial
VORINOSTAT BAP1

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22038994

Sources:
CIViC
VORINOSTAT HDAC10

Interaction Score: 0.45

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
21548582 20491440 19084294 22260166 19344175 23622981 19966789 26211462

Sources:
TALC DTC ClearityFoundationClinicalTrial
VORINOSTAT HDAC8

Interaction Score: 0.44

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
23622981 19966789 26211462 25974739 21548582 20491440 19084294 22260166 19344175

Sources:
TALC DTC TEND
VORINOSTAT HDAC7

Interaction Score: 0.42

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources:
TALC DTC MyCancerGenome
VORINOSTAT HDAC4

Interaction Score: 0.41

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18381238 23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources:
TALC DTC MyCancerGenome
VORINOSTAT SMARCB1

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Fenretinide + Vorinostat

Indication/Tumor Type rhabdoid cancer

Response Type sensitive

PMIDs:
23764045

Sources:
JAX-CKB
VORINOSTAT HDAC5

Interaction Score: 0.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources:
TALC DTC
VORINOSTAT EZH2

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type diffuse large B-cell lymphoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
25605023

Sources:
JAX-CKB
VORINOSTAT FBXW7

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type head and neck squamous cell carcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
23274910

Sources:
JAX-CKB
VORINOSTAT NPM1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type sensitive

combination therapy Ixazomib + Vorinostat

Indication/Tumor Type acute myeloid leukemia

PMIDs:
26634271

Sources:
JAX-CKB
VORINOSTAT RB1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type retinoblastoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
18483379 23498719

Sources:
JAX-CKB
VORINOSTAT CFTR

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19966789

Sources:
DTC
VORINOSTAT NR0B1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VORINOSTAT TUBA3C

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBB4A

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT BIRC5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16951239

Sources:
NCI
VORINOSTAT MYC

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15583844

Sources:
NCI
VORINOSTAT TUBB6

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBB2B

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBA4A

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBB8

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBA1C

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBA3E

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBA1B

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBA3D

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBB2A

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBA1A

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBB3

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBB4B

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBB

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT TUBB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20491440

Sources:
DTC
VORINOSTAT ACE

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24074025

Sources:
DTC
VORINOSTAT PTEN

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC-0941 + vorinostat

Indication/Tumor Type prostate cancer

Response Type sensitive

PMIDs:
9661880 22693356

Sources:
JAX-CKB
VORINOSTAT BRAF

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
27924459

Sources:
JAX-CKB
VORINOSTAT PAX8

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VORINOSTAT TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pazopanib + Vorinostat

Indication/Tumor Type Advanced Solid Tumor

Response Type decreased response

PMIDs:
25669829 26009011

Sources:
JAX-CKB CIViC
VORINOSTAT GMNN

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VORINOSTAT NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: VORINOSTAT
- Version: 01-August-2011
Alternate Names:

VORINOSTAT Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 2006

Publications:
MyCancerGenome: VORINOSTAT
- Version: 20-Jun-2017
Alternate Names:

ZOLINZA Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Cutaneous T-cell lymphoma

Publications:
TdgClinicalTrial: VORINOSTAT
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

DTC: VORINOSTAT

Version: 02-September-2020

Alternate Names:

CHEMBL98 ChEMBL Drug ID

Drug Info:

Publications:

Souto JA et al., 2010, Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues., J Med Chem

Grolla AA et al., 2009, Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases., J Med Chem

Hutt DM et al., 2010, Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis., Nat Chem Biol

NCI: SAHA

Version: 14-September-2017

Alternate Names:

C1796 NCI drug code

Drug Info:

Publications:

Xu et al., 2005, The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines., Int. J. Mol. Med.

Kulp et al., 2006, Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer., Clin. Cancer Res.

JAX-CKB: Vorinostat

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

New et al., 2016, TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism., Cancer Res.

Garcia et al., 2016, Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species., Clin. Cancer Res.

Kerl et al., 2013, The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells., BMC Cancer

JAX-CKB: vorinostat

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Qian et al., 2012, Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling., Clin. Cancer Res.

Vlietstra et al., 1998, Frequent inactivation of PTEN in prostate cancer cell lines and xenografts., Cancer Res.

PharmGKB: vorinostat
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Geeleher P et al., 2015, Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics., J Natl Cancer Inst

CIViC: VORINOSTAT

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Landreville et al., 2012, Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma., Clin. Cancer Res.

Fu et al., 2015, Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation., Ann. Oncol.

TALC: VORINOSTAT
- Version: 12-May-2016
Alternate Names:

VORINOSTAT Primary Drug Name

VORINOSTAT Drug Generic Name

ZOLINZA Drug Trade Name

Drug Info:

Publications:
TTD: Vorinostat
- Version: 2020.06.01
Alternate Names:

D0E7PQ TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL98
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: VORINOSTAT
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL98
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: VORINOSTAT
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:

Trial Name	Merck
Novel drug target	Established target
Mechanism of Interaction	Histone deacetylase 6 inhibitor

Notes
Mechanism of Interaction	Histone deacetylase 2 inhibitor
Direct Interaction	yes

Direct Interaction	yes
Mechanism of Interaction	Histone deacetylase 3 inhibitor
Notes

Mechanism of Interaction	Histone deacetylase 1 inhibitor
Direct Interaction	yes
Trial Name	Merck

Indication/Tumor Type	diffuse large B-cell lymphoma
Response Type	sensitive
Approval Status	Preclinical - Cell culture

combination therapy	Fenretinide + Vorinostat
Indication/Tumor Type	rhabdoid cancer
Response Type	sensitive

Indication/Tumor Type	head and neck squamous cell carcinoma
Response Type	sensitive
Approval Status	Preclinical

Indication/Tumor Type	retinoblastoma
Response Type	sensitive
Approval Status	Preclinical - Cell culture

combination therapy	GDC-0941 + vorinostat
Indication/Tumor Type	prostate cancer
Response Type	sensitive

Evidence Type	Actionable
Approval Status	Preclinical - Cell line xenograft
Response Type	sensitive

combination therapy	Pazopanib + Vorinostat
Indication/Tumor Type	Advanced Solid Tumor
Response Type	decreased response

VORINOSTAT	Primary Drug Name
VORINOSTAT	Drug Generic Name
ZOLINZA	Drug Trade Name

VORINOSTAT Drug Record

VORINOSTAT chembl:CHEMBL98 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26296641

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Merck Novel drug target Established target Mechanism of Interaction Histone deacetylase 6 inhibitor

PMIDs: 23622981 19966789 24766560 26211462 21696956 21080647 21548582 20491440 24304348 26331334 19084294 23672185 22260166 19344175 17694093

Sources: TALC DTC TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Mechanism of Interaction Histone deacetylase 2 inhibitor Direct Interaction yes

PMIDs: 23622981 19966789 26211462 21548582 20491440 23672185 19084294 22260166 19344175 24074025 17447750 24694055 17694093

Sources: TALC DTC TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Histone deacetylase 3 inhibitor Notes

PMIDs: 17447750 23622981 19966789 26211462 24694055 23672185 21548582 20491440 19084294 22260166 19344175 17694093

Sources: TALC DTC TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Histone deacetylase 1 inhibitor Direct Interaction yes Trial Name Merck

PMIDs: 17694093 11752352 23622981 19966789 26211462 21548582 20491440 24694055 19084294 23672185 22260166 19344175 18381238

Sources: TALC DTC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type diffuse large B-cell lymphoma Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 27733371

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources: TALC DTC MyCancerGenome ClearityFoundationClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources: TALC DTC ClearityFoundationClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22038994

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 21548582 20491440 19084294 22260166 19344175 23622981 19966789 26211462

Sources: TALC DTC ClearityFoundationClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 23622981 19966789 26211462 25974739 21548582 20491440 19084294 22260166 19344175

Sources: TALC DTC TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources: TALC DTC MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 18381238 23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources: TALC DTC MyCancerGenome

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Fenretinide + Vorinostat Indication/Tumor Type rhabdoid cancer Response Type sensitive

PMIDs: 23764045

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources: TALC DTC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type diffuse large B-cell lymphoma Response Type sensitive Approval Status Preclinical

PMIDs: 25605023

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type head and neck squamous cell carcinoma Response Type sensitive Approval Status Preclinical

PMIDs: 23274910

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Response Type sensitive combination therapy Ixazomib + Vorinostat Indication/Tumor Type acute myeloid leukemia

PMIDs: 26634271

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type retinoblastoma Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 18483379 23498719

Interaction Types & Directionality:

n/a

PMIDs:
26296641

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Merck

Novel drug target Established target

Mechanism of Interaction Histone deacetylase 6 inhibitor

PMIDs:
23622981 19966789 24766560 26211462 21696956 21080647 21548582 20491440 24304348 26331334 19084294 23672185 22260166 19344175 17694093

Sources:
TALC DTC TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Histone deacetylase 2 inhibitor

Direct Interaction yes

PMIDs:
23622981 19966789 26211462 21548582 20491440 23672185 19084294 22260166 19344175 24074025 17447750 24694055 17694093

Sources:
TALC DTC TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Histone deacetylase 3 inhibitor

Notes

PMIDs:
17447750 23622981 19966789 26211462 24694055 23672185 21548582 20491440 19084294 22260166 19344175 17694093

Sources:
TALC DTC TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Histone deacetylase 1 inhibitor

Direct Interaction yes

Trial Name Merck

PMIDs:
17694093 11752352 23622981 19966789 26211462 21548582 20491440 24694055 19084294 23672185 22260166 19344175 18381238

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type diffuse large B-cell lymphoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
27733371

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources:
TALC DTC MyCancerGenome ClearityFoundationClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources:
TALC DTC ClearityFoundationClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
22038994

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
21548582 20491440 19084294 22260166 19344175 23622981 19966789 26211462

Sources:
TALC DTC ClearityFoundationClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
23622981 19966789 26211462 25974739 21548582 20491440 19084294 22260166 19344175

Sources:
TALC DTC TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources:
TALC DTC MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18381238 23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources:
TALC DTC MyCancerGenome

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Fenretinide + Vorinostat

Indication/Tumor Type rhabdoid cancer

Response Type sensitive

PMIDs:
23764045

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175

Sources:
TALC DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type diffuse large B-cell lymphoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
25605023

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type head and neck squamous cell carcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
23274910

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type sensitive

combination therapy Ixazomib + Vorinostat

Indication/Tumor Type acute myeloid leukemia

PMIDs:
26634271

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type retinoblastoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
18483379 23498719

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
19966789

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC